Rhythm reports Imcivree’s key weight loss data from Phase 2 Prader-Willi trialnews2025-12-11T16:17:38+00:00December 11th, 2025|Endpoints News|
AC Immune says early biomarker data are promising in Parkinson’s, but clinical benefit remains unclearnews2025-12-11T15:31:37+00:00December 11th, 2025|Endpoints News|
Corbus’ obesity pill posts muted weight loss data; Disco adds another €16M in seed fundingnews2025-12-11T15:15:16+00:00December 11th, 2025|Endpoints News|
Health tech investors are getting creative with exitsnews2025-12-11T14:00:06+00:00December 11th, 2025|Endpoints News|
Zealand inks deal with OTR Therapeutics as it spells out broader metabolic disease ambitionsnews2025-12-11T12:12:44+00:00December 11th, 2025|Endpoints News|
Weight loss biotech Prolynx gets $70M, snags Amgen’s obesity commercial leader as CEOnews2025-12-11T12:00:12+00:00December 11th, 2025|Endpoints News|
Endpoints 100 survey 2025: Biotech CEOs are feeling more upbeatnews2025-12-11T12:00:03+00:00December 11th, 2025|Endpoints News|
Lilly’s triple agonist posts strongest weight loss data yet, unusual skin side effect also reportednews2025-12-11T11:45:15+00:00December 11th, 2025|Endpoints News|
House backs Biosecure Act aimed at Chinese companiesnews2025-12-11T09:52:38+00:00December 11th, 2025|Endpoints News|
Investors buy up stocks in biggest follow-on offering day in biotech historynews2025-12-10T19:50:58+00:00December 10th, 2025|Endpoints News|
